ArticleEndocrine connections2026
Changes in fibroblast growth factor 21 levels associated with alcohol consumption and smoking cessation.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Background: Alcohol consumption was shown to increase endogenous fibroblast growth factor 21 (FGF21), but knowledge about the effect of alcohol cessation on FGF21 is limited. The effects of cigarette smoking and cessation on FGF21 levels are unknown. The objective of this study was to investigate moderate alcohol and cigarette consumption and their cessation on FGF21 levels. Methods: This is a secondary analysis of two prospective intervention studies. Study 1: ten healthy men undergoing a beer or water intervention with blood sampling over 720 min. Differences in FGF21 levels between alcohol and water intake were assessed using a mixed-effect model. Study 2: 144 alcohol-drinking men or women undergoing a 12-week intervention of glucagon-like peptide 1 (GLP-1) receptor agonist dulaglutide vs placebo on smoking and alcohol cessation. Differences in FGF21 levels after 12 weeks of treatment with GLP-1 in persistent drinkers/smokers compared to those who had stopped drinking/smoking, were assessed using mixed-effect models. Results: Study 1: FGF21 levels at 240 min following beer intake were higher compared to water intake (1.386.0 pg/mL (95% CI: 934.55; 1,837.44), P < 0.001). Study 2: participants who stopped drinking alcohol had lower FGF21 levels compared to persistent drinkers (-228.65 pg/mL (95% CI: -440.4; -14.6), P = 0.03). Smoking cessation had no effect on FGF21 levels (P = 0.13). Conclusion: Our findings demonstrate a dynamic response in FGF21 levels, with acute moderate alcohol consumption inducing elevated FGF21 levels, and cessation of drinking lowering FGF21 levels, indicative of potential liver recovery. No effect of cigarette smoking cessation on plasma FGF21 levels was observed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.